PUBLICLY traded company. After 9 years of research, Blake announces IPO
Blake Insomnia Therapeutics, Inc. (BKIT) is a New York-based pharmaceutical company dedicated to improving nighttime and daytime quality of life for people with insomnia. After 9 years of research, and with our ZleepaxTM insomnia medication ready to enter Phase II clinical testing, we are pleased to announce our IPO on the NASDAQ OTC exchange.
ZLX-1, the first ZleepaxTM candidate covered by our patent, has demonstrated efficacy without producing the side effects identified as the No. 1 problem with current sleep medication. Instead of “knocking you out” the way traditional hypnotics do, ZleepaxTM enhances sleep by reducing the nighttime stress that often triggers and reinforces insomnia.
GREAT oportunity. Invest in a poten- tial blockbuster entering Phase II testing
Blake Insomnia will be issuing new shares to raise a single digit USD million, to complete Phase II clinical testing of our patent-pending ZLX-1 compound. We couldn’t be more enthused about our prospects for rapid approval, and we would like to invite you to be part of our exciting success story.
Copyright 2016 © All Rights Reserved